Drugs / GLA-SE
GLA-SE
also known as
GLA-SE adjuvant · Glucopyranosyl lipid A Stable emulsion · Glucopyranosyl Lipid A- Stable oil-in-water emulsion · Glucopyranosyl Lipid Adjuvant-Stable Emulsion · AP 10-201 · glucopyranosil lipid adjuvant stable emulsion · Glucopyranosyl lipid A · Glucopyranosyl Lipid A in Stable Emulsion · +2 more
Other / unclassified targets TLR4 via activation
Trials 26 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 12 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT05762393 Background | Nov 2023 → May 2025 | schistosomiasis | International Vaccine Institute | Completed | No outcome recorded |
| Phase 1 | NCT05182125 Background | Nov 2021 → Aug 2023 | HIV infectious disease | HIV Vaccine Trials Network | Completed | No outcome recorded |
| Phase 1 | NCT03856996 Background | May 2019 → Mar 2021 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT03722472 Background | Oct 2018 → Jun 2020 | pulmonary tuberculosis | Access to Advanced Health Institute (AAHI) | Completed | No outcome recorded |
| Phase 1 | NCT03409276 Background | Mar 2018 → May 2020 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT03302897 Background | Oct 2017 → Mar 2019 | leprosy | Access to Advanced Health Institute (AAHI) | Completed | No outcome recorded |
| Phase 1 | NCT03220724 Background | Aug 2017 → Mar 2023 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT02647489 Background | May 2016 → Nov 2017 | malaria | University Hospital Tuebingen | Completed | No outcome recorded |
| Phase 1 | NCT02015416 Background | Nov 2013 → Dec 2016 | breast cancer, melanoma, non-small cell lung carcinoma, ovarian cancer +1 | Immune Design | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03947437 Background | Feb → Mar 2024 | leprosy | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05658614 Background | Jul 2022 → Sep 2023 | Schistosoma mansoni infectious disease | Oswaldo Cruz Foundation | Unknown | No outcome recorded |
| Phase 2 | NCT03799510 Background | Dec 2018 → Jul 2019 | schistosomiasis | Oswaldo Cruz Foundation | Completed | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 40 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLA-SE | “intramuscular administration to Swiss volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)” NCT01949909 ↗34“2 μg LEP-F1 + 5 μg GLA-SE will be administered by IM injection on Days 0,28, and 56 in healthy participants.” NCT06627257 ↗ “The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.” NCT06714513 ↗ “Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-SE)” NCT03856996 ↗ “NY-ESO-1 recombinant protein together with GLA-SE” NCT02015416 ↗ “GLA-SE” NCT02320305 ↗ |
| Known as | AP 10-201 | “GLA-SE (glucopyranosyl lipid A - stable emulsion; [labeled as AP 10-201])” NCT05182125 ↗ |
| Known as | GLA-SE adjuvant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03409276 ↗ |
| Known as | glucopyranosil lipid adjuvant stable emulsion | “P27A antigen (10 or 50 μg), adjuvanted with Alhydrogel or glucopyranosil lipid adjuvant stable emulsion (GLA-SE; 2.5 or 5 μg), or control rabies vaccine (Verorab) were...” PMID 29945169 ↗ Jan 2019 |
| Known as | Glucopyranosyl lipid A | “GLA-SE- synthetic Glucopyranosyl lipid A in stable emulsion: 2.5ug / injection” NCT05658614 ↗ |
| Known as | Glucopyranosyl Lipid A in Stable Emulsion | “Glucopyranosyl Lipid A in Stable Emulsion” NCT03041766 ↗ |
| Known as | Glucopyranosyl lipid A Stable emulsion | “The vaccine consists of the recombinant four-antigen Mycobacterium leprae antigen LEP-F1 in combination with the adjuvant formulation GLA-SE (Glucopyranosyl Lipid A - Stable...” NCT03302897 ↗1“Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant” NCT01540474 ↗ |
| Known as | Glucopyranosyl Lipid A- Stable oil-in-water emulsion | “Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE) is formulated in a stable oil-in-water emulsion (SE) to yield the adjuvant formulation GLA-SE.” NCT01751048 ↗1“Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE). The ID93 (10 mcg) + GLA-SE (5 mcg) arm will receive intervention on days 1, 29 and 57” NCT02508376 ↗ |
| Known as | Glucopyranosyl Lipid Adjuvant-Stable Emulsion | “Glucopyranosyl Lipid Adjuvant-Stable Emulsion” NCT03041766 ↗ |
| Known as | Glucopyranosyl-lipid adjuvant in squalene emulsion | “Glucopyranosyl-lipid adjuvant in squalene emulsion (GLA-SE)” NCT01991561 ↗ |
| Known as | Toll-like Receptor 4 Agonist GLA-SE | “Toll-like Receptor 4 Agonist GLA-SE” NCT03041766 ↗ |
| Action | Activate | “The TLR-4 agonist adjuvant, GLA-SE” PMID 30210819 ↗ Sep 2018 |
| Modality | Other / unclassified | “a proprietary adjuvant” NCT01540474 ↗ |
| Route | Intramuscular | “Administered Intramuscularly” NCT01540474 ↗ |
| Target | TLR4 | “a Toll-like Receptor-4 Agonist” NCT02035657 ↗ |